TrovaGene, Inc. (NASDAQ:TROV) PT Set at $4.00 by Maxim Group
Maxim Group set a $4.00 price objective on TrovaGene, Inc. (NASDAQ:TROV) in a research report sent to investors on Thursday. The brokerage currently has a buy rating on the medical research company’s stock.
Shares of TrovaGene (NASDAQ:TROV) opened at 0.8763 on Thursday. The firm’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.32. The company’s market capitalization is $27.14 million. TrovaGene has a 12 month low of $0.61 and a 12 month high of $5.98.
An institutional investor recently raised its position in TrovaGene stock. Two Sigma Securities LLC boosted its stake in TrovaGene, Inc. (NASDAQ:TROV) by 262.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 120,516 shares of the medical research company’s stock after buying an additional 87,264 shares during the period. Two Sigma Securities LLC owned 0.39% of TrovaGene worth $139,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.19% of the company’s stock.
TrovaGene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.